Alto Neuroscience (ANRO) News Today → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Free ANRO Stock Alerts $12.47 -0.35 (-2.73%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 2:17 AM | americanbankingnews.comQ2 2024 Earnings Forecast for Alto Neuroscience, Inc. Issued By William Blair (NYSE:ANRO)May 17 at 7:50 AM | marketbeat.comQ2 2024 Earnings Estimate for Alto Neuroscience, Inc. Issued By William Blair (NYSE:ANRO)Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Research analysts at William Blair lowered their Q2 2024 earnings per share (EPS) estimates for Alto Neuroscience in a note issued to investors on Wednesday, May 15th. William Blair analyst M. Minter now anticipates that the company will post eaMay 17 at 4:18 AM | americanbankingnews.comAlto Neuroscience (NYSE:ANRO) Stock Rating Reaffirmed by William BlairMay 16, 2024 | markets.businessinsider.comBuy Rating for Alto Neuroscience: Promising Trials in MDD and Advances in CIAS TreatmentMay 16, 2024 | bloomberg.comAlto Aims to Redefine Psychiatry Landscape: Vanguards of Health CareMay 15, 2024 | marketbeat.comAlto Neuroscience (NYSE:ANRO) Earns "Outperform" Rating from William BlairWilliam Blair restated an "outperform" rating on shares of Alto Neuroscience in a research note on Wednesday.May 14, 2024 | msn.comANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024May 14, 2024 | finance.yahoo.comAlto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 9, 2024 | finance.yahoo.comAlto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific ConferencesApril 23, 2024 | markets.businessinsider.comTreatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry LandscapeApril 23, 2024 | businesswire.comAlto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for SchizophreniaApril 3, 2024 | finance.yahoo.comAlto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive DisorderApril 2, 2024 | insidertrades.comAlto Neuroscience, Inc. (NYSE:ANRO) CFO Purchases $100,614.00 in StockApril 1, 2024 | marketbeat.comAlto Neuroscience, Inc. (NYSE:ANRO) CFO Nicholas Conrad Smith Buys 6,150 SharesAlto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) CFO Nicholas Conrad Smith purchased 6,150 shares of the stock in a transaction dated Thursday, March 28th. The shares were purchased at an average cost of $16.36 per share, for a total transaction of $100,614.00. Following the transaction, the chief financial officer now owns 26,866 shares in the company, valued at approximately $439,527.76. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.March 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alto Neuroscience on Strong Pipeline and Solid FinancialsMarch 25, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Alto Neuroscience, Inc. (ANRO)March 25, 2024 | marketbeat.comStifel Nicolaus Reaffirms "Buy" Rating for Alto Neuroscience (NYSE:ANRO)Stifel Nicolaus reissued a "buy" rating and set a $32.00 price target on shares of Alto Neuroscience in a research report on Monday.March 25, 2024 | markets.businessinsider.comBuy Rating Affirmed: Alto Neuroscience’s Promising Clinical Trials Signal Market PotentialMarch 21, 2024 | businesswire.comAlto Neuroscience Reports Full Year 2023 Financial Results and Recent Business HighlightsMarch 11, 2024 | finance.yahoo.comAlto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of DirectorsMarch 7, 2024 | finance.yahoo.comAlto Neuroscience to Participate in Upcoming Investor ConferencesFebruary 29, 2024 | marketbeat.comWilliam Blair Comments on Alto Neuroscience, Inc.'s FY2023 Earnings (NYSE:ANRO)Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Stock analysts at William Blair issued their FY2023 EPS estimates for Alto Neuroscience in a research note issued to investors on Tuesday, February 27th. William Blair analyst M. Minter forecasts that the company will earn ($11.78) per share forFebruary 27, 2024 | uk.investing.comAnalysts bullish on Alto NeuroscienceFebruary 27, 2024 | msn.comStifel, Baird, Jefferies bullish on Alto Neuroscience, cite upcoming dataFebruary 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alto Neuroscience Amid Promising Precision Neuropsychiatric TreatmentsFebruary 27, 2024 | marketbeat.comAlto Neuroscience (NYSE:ANRO) Now Covered by William BlairWilliam Blair began coverage on Alto Neuroscience in a research report on Tuesday. They issued an "outperform" rating for the company.February 27, 2024 | businesswire.comAlto Neuroscience to Present at the TD Cowen 44th Annual Healthcare ConferenceFebruary 13, 2024 | morningstar.comAlto Neuroscience Inc ANROFebruary 13, 2024 | uk.investing.comAlto Neuroscience Inc (ANRO)February 13, 2024 | cnn.comAlto Neuroscience, Inc.February 12, 2024 | finance.yahoo.comAlto Neuroscience, Inc. (ANRO)February 12, 2024 | finance.yahoo.comAlto Neuroscience Announces Pricing of Upsized Initial Public OfferingFebruary 12, 2024 | finance.yahoo.comAlto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Next President (Not Trump. Not Biden.) (Ad)Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump. Click here to see why it will be ______ _________. ANRO Media Mentions By Week ANRO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANRO News Sentiment▼-0.220.42▲Average Medical News Sentiment ANRO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANRO Articles This Week▼132▲ANRO Articles Average Week Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Mersana Therapeutics News Today Ventyx Biosciences News Today ADC Therapeutics News Today Nanobiotix News Today Erasca News Today Nkarta News Today Nektar Therapeutics News Today Precigen News Today Vanda Pharmaceuticals News Today Revance Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ANRO) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceBiden Nomination CANCELED?The Freeport SocietyUrgent Nvidia WarningAltimetryShocking: One AI startup's revenue could surge 4,735%Manward Press"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist My Default Watchlist Adding Alto Neuroscience, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
